The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Markets Update: Financial Services Outlook
The Outlook for a Commodities Bull Market in 2021
Markets Update: Looking Back on 2020’s Roller Coaster Ride
Gregg Lemkau on How Investment Banking has Changed in his 28 Years at Goldman Sachs
Markets Update: What Investors Are Watching Going into Year-End
November Wrap: Record Inflows into Global Equities
Asia-Pacific Economic Outlook for 2021
Markets Update: The Bull Run in 2021
Germany’s Economic Recovery
Markets Update: A Biden Presidency, a Possible Vaccine and the Future of the S&P
Vaccine Progress and What’s Next
Client Call: Macro Outlook 2021
Markets Update: Investors Feel “Relief” As Clarity Begins to Form Around US Election
Markets Update: Investors Anticipate Next Week’s US Election
How Entrepreneurs are Leading Their Companies Through an Unexpected Year
Markets Update: Election Outlook
An Update on the LIBOR Transition and Why It Matters for Wall Street and Main Street
Markets Update: Taking Stock of Year-to-Date Performance
The State of Small Businesses in the U.K.
Markets Update: Investor Sentiment Tilts Marginally Bullish and Pro-Cyclical
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money